SG Americas Securities’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-10,909
| Closed | -$1.88M | – | 3998 |
|
|
2021
Q3 | $1.88M | Sell |
10,909
-6,077
| -36% | -$795K | 0.01% | 1327 |
|
|
2021
Q2 | $2.13M | Buy |
16,986
+687
| +4% | +$86.6K | 0.01% | 1086 |
|
|
2021
Q1 | $2.21M | Buy |
16,299
+15,235
| +1,432% | +$1.97M | 0.01% | 981 |
|
|
2020
Q4 | $136K | Sell |
1,064
-6,244
| -85% | -$732K | ﹤0.01% | 2877 |
|
|
2020
Q3 | $822K | Buy |
7,308
+5,246
| +254% | +$522K | 0.01% | 1308 |
|
|
2020
Q2 | $196K | Sell |
2,062
-50,323
| -96% | -$4.85M | ﹤0.01% | 2877 |
|
|
2020
Q1 | $4.71M | Buy |
52,385
+45,686
| +682% | +$3.55M | 0.04% | 403 |
|
|
2019
Q4 | $355K | Buy |
6,699
+3,898
| +139% | +$178K | ﹤0.01% | 2057 |
|
|
2019
Q3 | $111K | Sell |
2,801
-8,214
| -75% | -$356K | ﹤0.01% | 2680 |
|
|
2019
Q2 | $452K | Sell |
11,015
-4,383
| -28% | -$181K | ﹤0.01% | 1948 |
|
|
2019
Q1 | $717K | Sell |
15,398
-23,790
| -61% | -$1.04M | 0.01% | 1534 |
|
|
2018
Q4 | $1.71M | Buy |
+39,188
| New | +$1.96M | 0.01% | 978 |
|
|
2018
Q3 | – | Sell |
-2,069
| Closed | -$100K | – | 3566 |
|
|
2018
Q2 | $100K | Sell |
2,069
-713
| -26% | -$26K | ﹤0.01% | 3084 |
|
|
2018
Q1 | $109K | Buy |
+2,782
| New | +$118K | ﹤0.01% | 2899 |
|
|
2017
Q4 | – | Sell |
-12,239
| Closed | -$457K | – | 3787 |
|
|
2017
Q3 | $457K | Buy |
12,239
+7,566
| +162% | +$263K | ﹤0.01% | 1912 |
|
|
2017
Q2 | $142K | Sell |
4,673
-191
| -4% | -$5.54K | ﹤0.01% | 2671 |
|
|
2017
Q1 | $129K | Sell |
4,864
-11,486
| -70% | -$303K | ﹤0.01% | 2798 |
|
|
2016
Q4 | $417K | Buy |
16,350
+7,501
| +85% | +$238K | ﹤0.01% | 1818 |
|
|
2016
Q3 | $320K | Buy |
+8,849
| New | +$293K | ﹤0.01% | 2116 |
|
|
2016
Q2 | – | Sell |
-5,642
| Closed | -$149K | – | 3117 |
|
|
2016
Q1 | $149K | Buy |
+5,642
| New | +$164K | ﹤0.01% | 2375 |
|
|
2015
Q3 | – | Sell |
-4,513
| Closed | -$143K | – | 2839 |
|
|
2015
Q2 | $143K | Buy |
+4,513
| New | +$146K | ﹤0.01% | 2159 |
|
|
2015
Q1 | – | Sell |
-4,054
| Closed | -$158K | – | 3193 |
|
|
2014
Q4 | $158K | Buy |
+4,054
| New | +$141K | ﹤0.01% | 2614 |
|
|
2014
Q2 | – | Sell |
-9,228
| Closed | -$318K | – | 2767 |
|
|
2014
Q1 | $318K | Buy |
+9,228
| New | +$416K | ﹤0.01% | 1711 |
|
SG Americas Securities's XLRN Position: Q4 2021 in Review
SG Americas Securities sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 10,909 shares — an estimated $1.88M sold.
SG Americas Securities first reported a position in XLRN in Q1 2014 and held it in 23 quarters. The position peaked at $4.71M in Q1 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- SG Americas Securities reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- SG Americas Securities sold 10,909 Acceleron Pharma shares in Q4 2021, an estimated $1.88M.
- SG Americas Securities first reported a position in Acceleron Pharma in Q1 2014 and held it in 23 quarters.
- SG Americas Securities's Acceleron Pharma position peaked at $4.71M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on SG Americas Securities's 13F filing for Q4 2021, filed 7 Feb 2022.